We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(Kaiser Health News) Apr 23, 2018 - In an ominous sign for patient safety, 71 percent of reusable medical scopes deemed ready for use on patients tested positive for bacteria at three major U.S. hospitals, according to a new study.
(PharmaTimes [UK]) Apr 24, 2018 - European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
(STAT Plus) Apr 23, 2018 - Between 2012 and early 2017, Insys provided at least $2.5 million to U.S. Pain Foundation, a nonprofit organization, and the money was earmarked for a patient assistance program called Gain for Pain.
(Reuters) Apr 24, 2018 - Sanofi said on Tuesday it had hired former Roche top scientist John Reed to head its research operations from July 1, when Elias Zerhouni retires from the French drugmaker.
(Reuters) Apr 24, 2018 - The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.
(MarketWatch) Apr 24, 2018 - Bayer is pleased to announce another year of partnership with patient advocacy organizations Colorectal Cancer Alliance (the Alliance) and Fight Colorectal Cancer (Fight CRC).
(Xconomy Boston) Apr 23, 2018 - Epizyme said Monday that a pediatric patient taking its experimental cancer drug tazemetostat developed a new cancer, different than the one tazemetostat had been treating.
(WIVB-TV, Ch. 4 [Williamsville, NY]) Apr 24, 2018 - Some CCS Oncology patients are still trying to figure out where they will continue their cancer treatments.
(MD Anderson) Apr 23, 2018 - A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
(AJMC Managed Markets Network) Apr 20, 2018 - Reimbursement models, novel gene therapy–based treatments, and price transparency: these were some of the topics covered by presenters and panelists at the annual meeting of the Community Oncology Alliance.